S&P 500   3,155.24 (+0.86%)
DOW   27,271.07 (+0.70%)
QQQ   218.10 (+1.27%)
AAPL   291.89 (+1.32%)
FB   199.65 (+1.46%)
MSFT   170.81 (+1.63%)
AMZN   1,989.48 (+0.85%)
NVDA   269.23 (+2.74%)
MU   53.58 (+2.84%)
GE   11.27 (-0.44%)
TSLA   787.06 (-1.61%)
AMD   48.67 (+2.31%)
ACB   1.51 (-0.66%)
F   7.39 (+2.07%)
NFLX   372.28 (+3.39%)
PRI   123.00 (+1.30%)
BAC   31.35 (+0.87%)
DIS   126.74 (-1.13%)
S&P 500   3,155.24 (+0.86%)
DOW   27,271.07 (+0.70%)
QQQ   218.10 (+1.27%)
AAPL   291.89 (+1.32%)
FB   199.65 (+1.46%)
MSFT   170.81 (+1.63%)
AMZN   1,989.48 (+0.85%)
NVDA   269.23 (+2.74%)
MU   53.58 (+2.84%)
GE   11.27 (-0.44%)
TSLA   787.06 (-1.61%)
AMD   48.67 (+2.31%)
ACB   1.51 (-0.66%)
F   7.39 (+2.07%)
NFLX   372.28 (+3.39%)
PRI   123.00 (+1.30%)
BAC   31.35 (+0.87%)
DIS   126.74 (-1.13%)
S&P 500   3,155.24 (+0.86%)
DOW   27,271.07 (+0.70%)
QQQ   218.10 (+1.27%)
AAPL   291.89 (+1.32%)
FB   199.65 (+1.46%)
MSFT   170.81 (+1.63%)
AMZN   1,989.48 (+0.85%)
NVDA   269.23 (+2.74%)
MU   53.58 (+2.84%)
GE   11.27 (-0.44%)
TSLA   787.06 (-1.61%)
AMD   48.67 (+2.31%)
ACB   1.51 (-0.66%)
F   7.39 (+2.07%)
NFLX   372.28 (+3.39%)
PRI   123.00 (+1.30%)
BAC   31.35 (+0.87%)
DIS   126.74 (-1.13%)
S&P 500   3,155.24 (+0.86%)
DOW   27,271.07 (+0.70%)
QQQ   218.10 (+1.27%)
AAPL   291.89 (+1.32%)
FB   199.65 (+1.46%)
MSFT   170.81 (+1.63%)
AMZN   1,989.48 (+0.85%)
NVDA   269.23 (+2.74%)
MU   53.58 (+2.84%)
GE   11.27 (-0.44%)
TSLA   787.06 (-1.61%)
AMD   48.67 (+2.31%)
ACB   1.51 (-0.66%)
F   7.39 (+2.07%)
NFLX   372.28 (+3.39%)
PRI   123.00 (+1.30%)
BAC   31.35 (+0.87%)
DIS   126.74 (-1.13%)
Log in

NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News

$2.91
+0.06 (+2.11 %)
(As of 02/26/2020 10:00 AM ET)
Today's Range
$2.79
Now: $2.91
$2.94
50-Day Range
$2.69
MA: $3.40
$4.28
52-Week Range
$1.13
Now: $2.91
$8.39
Volume108,321 shs
Average Volume801,306 shs
Market Capitalization$309.25 million
P/E Ratio2.14
Dividend YieldN/A
Beta1.07
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.21 million
Book Value($0.25) per share

Profitability

Net Income$-120,550,000.00

Miscellaneous

Employees202
Market Cap$309.25 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.


Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.80. The biopharmaceutical company had revenue of $294.45 million for the quarter, compared to analyst estimates of $12 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The company's revenue was up 4124.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.26) EPS. View Lexicon Pharmaceuticals' Earnings History.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals.

What price target have analysts set for LXRX?

6 brokers have issued twelve-month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 140.5% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

Press coverage about LXRX stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of 2.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Lexicon Pharmaceuticals.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,520,000 shares, an increase of 6.9% from the January 15th total of 13,580,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is currently 10.5 days. Currently, 14.1% of the shares of the stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.82%), Boxer Capital LLC (2.61%), Renaissance Technologies LLC (1.13%), State Street Corp (0.84%), Marshall Wace LLP (0.80%) and Bank of New York Mellon Corp (0.75%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Which institutional investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jacobs Levy Equity Management Inc., Bank of America Corp DE, Pinnacle Associates Ltd., State Street Corp, Jane Street Group LLC, Goldman Sachs Group Inc. and Wedbush Securities Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Which institutional investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of New York Mellon Corp, AQR Capital Management LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Spark Investment Management LLC, Boxer Capital LLC and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.91.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $309.25 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.


MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  433 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  857
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel